Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Curriu, Marta ^a   Carrillo, Jorge ^a   Massanella, Marta ^a   Rigau, Josepa ^b   Alegre, José ^c   Puig, Jordi ^d   Garcia Quintana, Ana M ^e   Castro Marrero, Jesus ^c   Negredo, Eugènia ^d   Clotet, Bonaventura ^a,d   Cabrera, Cecilia ^a   Blanco, Julià ^a,d  

^a FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^b CFS Clinic   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e Clinica Delfos   (Spain)

Author keywords

Immune activation; Immunosenescence; NKp46; T regulatory cells

Indexed keywords

CD69 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1;

ADULT; ARTICLE; B LYMPHOCYTE; CD4+ FOXP3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSENESCENCE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MEMORY CELL; NATURAL KILLER CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SCREENING TEST; SENESCENCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; B-LYMPHOCYTES; CD4-CD8 RATIO; CELL DEATH; CELL PROLIFERATION; CLUSTER ANALYSIS; COHORT STUDIES; FATIGUE SYNDROME, CHRONIC; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; LECTINS, C-TYPE; MALE; MIDDLE AGED; PHENOTYPE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84875062805     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-68     Document Type: Article

References (67)

1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994, 121:953-959.
2. Avellaneda Fernández A, Pérez Martín A, Izquierdo Martínez M, Arruti Bustillo M, Barbado Hernández FJ, de la Cruz Labrado J. Chronic fatigue syndrome: aetiology, diagnosis and treatment. BMC Psychiatry 2009, 9(Suppl 1):S1. 10.1186/1471-244X-9-S1-S1, 2766938, 19857242.
3. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med 2011, 270:327-338. 10.1111/j.1365-2796.2011.02428.x, 3427890, 21777306.
4. Morris G, Maes M. A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome. Metab Brain Dis 2012,
5. Jason LA, Corradi K, Torres-Harding S, Taylor RR, King C. Chronic fatigue syndrome: the need for subtypes. Neuropsychol Rev 2005, 15:29-58. 10.1007/s11065-005-3588-2, 15929497.
6. Papadopoulos AS, Cleare AJ. Hypothalamic-pituitary-adrenal axis dysfunction in chronic fatigue syndrome. Nat Rev Endocrinol 2012, 8:22-32.
7. Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS, Peterson DL. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009, 326:585-589. 10.1126/science.1179052, 19815723.
8. Silverman RH, Das Gupta J, Lombardi VC, Ruscetti FW, Pfost MA, Hagen KS. Partial retraction. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2011, 334:176.
9. Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Transl Med 2011, 9:81. 10.1186/1479-5876-9-81, 3120691, 21619669.
10. Bansal AS, Bradley AS, Bishop KN, Kiani-Alikhan S, Ford B. Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun 2012, 26:24-31. 10.1016/j.bbi.2011.06.016, 21756995.
11. Nijs J, Meeus M, Van Oosterwijck J, Ickmans K, Moorkens G, Hans G. In the mind or in the brain? Scientific evidence for central sensitisation in chronic fatigue syndrome. Eur J Clin Invest 2012, 42:203-212. 10.1111/j.1365-2362.2011.02575.x, 21793823.
12. Landay AL, Jessop C, Lennette ET, Levy JA. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991, 338:707-712. 10.1016/0140-6736(91)91440-6, 1679864.
13. Galbraith S, Cameron B, Li H, Lau D, Vollmer-Conna U, Lloyd AR. Peripheral blood gene expression in postinfective fatigue syndrome following from three different triggering infections. J Infect Dis 2011, 204:1632-1640. 10.1093/infdis/jir612, 21964398.
14. Chia J, Chia A, Voeller M, Lee T, Chang R. Acute enterovirus infection followed by myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and viral persistence. J Clin Pathol 2010, 63:165-168. 10.1136/jcp.2009.070466, 19828908.
15. Chia JKS, Chia AY. Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach. J Clin Pathol 2008, 61:43-48.
16. Kerr JR, Gough J, Richards SCM, Main J, Enlander D, McCreary M. Antibody to parvovirus B19 nonstructural protein is associated with chronic arthralgia in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J Gen Virol 2010, 91:893-897. 10.1099/vir.0.017590-0, 20007355.
17. Koelle DM, Barcy S, Huang M-L, Ashley RL, Corey L, Zeh J. Markers of viral infection in monozygotic twins discordant for chronic fatigue syndrome. Clin Infect Dis 2002, 35:518-525. 10.1086/341774, 12173124.
18. Watt T, Oberfoell S, Balise R, Lunn MR, Kar AK, Merrihew L. Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers. J Med Virol 2012, 84:1967-1974. 10.1002/jmv.23411, 23080504.
19. Fluge O, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D. Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study. PLoS One 2011, 6:e26358. 10.1371/journal.pone.0026358, 3198463, 22039471.
20. Fluge, Mella O. Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series. BMC Neurol 2009, 9:28. 10.1186/1471-2377-9-28, 2711959, 19566965.
21. Swanink CM, Vercoulen JH, Galama JM, Roos MT, Meyaard L, van der Ven-Jongekrijg J. Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome. J Infect Dis 1996, 173:460-463. 10.1093/infdis/173.2.460, 8568312.
22. Fletcher MA, Zeng XR, Maher K, Levis S, Hurwitz B, Antoni M. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS One 2010, 5:e10817. 10.1371/journal.pone.0010817, 2876037, 20520837.
23. Mihaylova I, DeRuyter M, Rummens J-L, Bosmans E, Maes M. Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells. Neuro Endocrinol Lett 2007, 28:477-483.
24. Buchwald D, Komaroff AL. Review of Laboratory Findings for Patients with Chronic Fatigue Syndrome. Rev Infect Dis 1991, 13:S12-S18. 10.1093/clinids/13.Supplement_1.S12, 1902321.
25. Fletcher MA, Zeng XR, Barnes Z, Levis S, Klimas NG. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009, 7:96. 10.1186/1479-5876-7-96, 2779802, 19909538.
26. Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun 2010, 24:1209-1217. 10.1016/j.bbi.2010.04.012, 2939140, 20447453.
27. Lombardi VC, Hagen KS, Hunter KW, Diamond JW, Smith-Gagen J, Yang W. Xenotropic murine leukemia virus-related virus-associated chronic fatigue syndrome reveals a distinct inflammatory signature. In Vivo 2011, 25:307-314.
28. Hanevik K, Kristoffersen EK, Sørnes S, Mørch K, Næss H, Rivenes AC. Immunophenotyping in post-giardiasis functional gastrointestinal disease and chronic fatigue syndrome. BMC Infect Dis 2012, 12:258. 10.1186/1471-2334-12-258, 3553045, 23061432.
29. Brenu EW, van Driel ML, Staines DR, Ashton KJ, Hardcastle SL, Keane J. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med 2012, 10:88. 10.1186/1479-5876-10-88, 3464733, 22571715.
30. Morrison LJ, Behan WH, Behan PO. Changes in natural killer cell phenotype in patients with post-viral fatigue syndrome. Clin Exp Immunol 1991, 83:441-446. 1535328, 1706238.
31. Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA. Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis 1994, 18(Suppl 1):S136-S141.
32. Stewart CC, Cookfair DL, Hovey KM, Wende KE, Bell DS, Warner CL. Predictive immunophenotypes: disease-related profile in chronic fatigue syndrome. Cytometry B Clin Cytom 2003, 53:26-33.
33. Robertson MJ, Schacterle RS, Mackin GA, Wilson SN, Bloomingdale KL, Ritz J. Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression. Clin Exp Immunol 2005, 141:326-332. 10.1111/j.1365-2249.2005.02833.x, 1809442, 15996197.
34. Massanella M, Negredo E, Pérez-Alvarez N, Puig J, Ruiz-Hernández R, Bofill M. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS 2010, 24:959-968. 10.1097/QAD.0b013e328337b957, 20177358.
35. Gress RE, Deeks SG. Reduced thymus activity and infection prematurely age the immune system. J Clin Invest 2009, 119:2884-2887. 10.1172/JCI40855, 2752092, 19770512.
36. Griffin DE. Measles virus-induced suppression of immune responses. Immunol Rev 2010, 236:176-189. 10.1111/j.1600-065X.2010.00925.x, 2908915, 20636817.
37. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370. 10.1111/j.1600-0447.1983.tb09716.x, 6880820.
38. Alijotas J, Alegre J, Fernández-Solà J, Cots JM, Panisello J, Peri JM. Consensus report on the diagnosis and treatment of chronique fatigue syndrome in Catalonia. Med Clin (Barc) 2002, 118:73-76.
39. Barretina J, Blanco J, Bonjoch A, Llano A, Clotet B, Esté JA. Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS 2004, 18:1673-1682. 10.1097/01.aids.0000131350.22032.b5, 15280778.
40. Negredo E, Massanella M, Puig J, Pérez-Alvarez N, Gallego-Escuredo JM, Villarroya J. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis 2010, 50:1300-1308. 10.1086/651689, 20367229.
41. Blanco J, Barretina J, Clotet B, Esté JA. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. J Leukoc Biol 2004, 76:804-811. 10.1189/jlb.0204100, 15258189.
42. Allegra S, Deleine C, Michael-Jubely R, Gryson C, Boirie Y, Kantakamalakul W. Implementation of the EGFP-K562 flow cytometric NK test: determination of NK cytotoxic activity in healthy elderly volunteers before and after feeding. Cytometry A 2006, 69:992-998.
43. Kantakamalakul W, Jaroenpool J, Pattanapanyasat K. A novel enhanced green fluorescent protein (EGFP)-K562 flow cytometric method for measuring natural killer (NK) cell cytotoxic activity. J Immunol Methods 2003, 272:189-197. 10.1016/S0022-1759(02)00505-7, 12505723.
44. Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009, 8:287-291. 10.1016/j.autrev.2008.08.003, 18801465.
45. Stricker RB, Winger EE. Decreased CD57 lymphocyte subset in patients with chronic Lyme disease. Immunol Lett 2001, 76:43-48. 10.1016/S0165-2478(00)00316-3, 11222912.
46. Appay V, van Lier RAW, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008, 73:975-983.
47. Appay V, Fastenackels S, Katlama C, Ait-Mohand H, Schneider L, Guihot A. Old age and anti-CMV immunity are associated with altered T cell reconstitution in HIV-1 infected patients. AIDS 2011, 25:1813-1822. 10.1097/QAD.0b013e32834640e6, 21412126.
48. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011, 62:141-155. 10.1146/annurev-med-042909-093756, 21090961.
49. Hawiger D, Masilamani RF, Bettelli E, Kuchroo VK, Nussenzweig MC. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 2004, 20:695-705. 10.1016/j.immuni.2004.05.002, 15189735.
50. Stamou P, de Jersey J, Carmignac D, Mamalaki C, Kioussis D, Stockinger B. Chronic exposure to low levels of antigen in the periphery causes reversible functional impairment correlating with changes in CD5 levels in monoclonal CD8 T cells. J Immunol 2003, 171:1278-1284.
51. Tirelli U, Marotta G, Improta S, Pinto A. Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol 1994, 40:601-608. 10.1111/j.1365-3083.1994.tb03511.x, 7997849.
52. Russell IJ, Vipraio GA, Michalek JE, Craig FE, Kang YK, Richards AB. Lymphocyte markers and natural killer cell activity in fibromyalgia syndrome: effects of low-dose, sublingual use of human interferon-alpha. J Interferon Cytokine Res 1999, 19:969-978. 10.1089/107999099313523, 10476945.
53. Soto NE, Straus SE. Chronic Fatigue Syndrome and Herpesviruses: the Fading Evidence. Herpes 2000, 7:46-50.
54. Jost S, Quillay H, Reardon J, Peterson E, Simmons RP, Parry BA. Changes in cytokine levels and NK cell activation associated with influenza. PLoS One 2011, 6:e25060. 10.1371/journal.pone.0025060, 3179484, 21966414.
55. Narni-Mancinelli E, Jaeger BN, Bernat C, Fenis A, Kung S, De Gassart A. Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses. Science 2012, 335:344-348. 10.1126/science.1215621, 22267813.
56. Sun JC, Beilke JN, Lanier LL. Immune memory redefined: characterizing the longevity of natural killer cells. Immunol Rev 2010, 236:83-94. 10.1111/j.1600-065X.2010.00900.x, 2907527, 20636810.
57. Gumá M, Cabrera C, Erkizia I, Bofill M, Clotet B, Ruiz L. Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis 2006, 194:38-41. 10.1086/504719, 16741880.
58. Gayoso I, Sanchez-Correa B, Campos C, Alonso C, Pera A, Casado JG. Immunosenescence of human natural killer cells. J Innate Immun 2011, 3:337-343. 10.1159/000328005, 21576928.
59. Gupta S, Vayuvegula B. A comprehensive immunological analysis in chronic fatigue syndrome. Scand J Immunol 1991, 33:319-327. 10.1111/j.1365-3083.1991.tb01777.x, 1849315.
60. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
61. Maes M, Leunis J-C. Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. Neuro Endocrinol Lett 2008, 29:902-910.
62. Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012, 30:531-564. 10.1146/annurev.immunol.25.022106.141623, 22224781.
63. Hall BM, Verma ND, Tran GT, Hodgkinson SJ. Distinct regulatory CD4 + T cell subsets; differences between naïve and antigen specific T regulatory cells. Curr Opin Immunol 2011, 23:641-647. 10.1016/j.coi.2011.07.012, 21840184.
64. Bennett AL, Chao CC, Hu S, Buchwald D, Fagioli LR, Schur PH. Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome. J Clin Immunol 1997, 17:160-166. 10.1023/A:1027330616073, 9083892.
65. Zhang H-Y, Liu Z-D, Hu C-J, Wang D-X, Zhang Y-B, Li Y-Z. Up-regulation of TGF-β1 mRNA expression in peripheral blood mononuclear cells of patients with chronic fatigue syndrome. J Formos Med Assoc 2011, 110:701-704. 10.1016/j.jfma.2011.09.006, 22118314.
66. Fletcher MA, Rosenthal M, Antoni M, Ironson G, Zeng XR, Barnes Z. Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome. Behav Brain Funct 2010, 6:76. 10.1186/1744-9081-6-76, 3024290, 21190576.
67. Brenu EW, Staines DR, Baskurt OK, Ashton KJ, Ramos SB, Christy RM. Immune and hemorheological changes in chronic fatigue syndrome. J Transl Med 2010, 8:1. 10.1186/1479-5876-8-1, 2829521, 20064266.